Deflazacort versus prednisone in patients with giant cell arteritis: Effects on bone mass loss

Journal of Rheumatology

Volumn 28, Issue 11, 2001, Pages 2474-2479

  Cacoub, P ^a   Chemlal, K ^a   Khalifa, P ^a   Wechsler, B ^a   De Gennes, C ^a   Belmatoug, N ^a   Cohen, P ^a   Ziza, J M ^a   Verdoncq, B ^a   Piette, J C ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Bone mass loss; Deflazacort; Giant cell arteritis; Glucocorticoids; Osteoporosis; Prednisone

Indexed keywords

CACIT 1000; CALCIFEDIOL; CALCIUM; DEFLAZACORT; PHOSPHATE; PREDNISONE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE MASS; BONE MINERAL; CALCIUM METABOLISM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GIANT CELL ARTERITIS; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OSTEOPOROSIS; PHOSPHATE METABOLISM; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STATISTICAL ANALYSIS; VERTEBRA FRACTURE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; BONE DENSITY; BONE DISEASES, METABOLIC; CALCIUM; DENSITOMETRY, X-RAY; DOUBLE-BLIND METHOD; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES; PREDNISONE; PREGNENEDIONES; PROSPECTIVE STUDIES; SPINAL FRACTURES; TEMPORAL ARTERITIS; TREATMENT OUTCOME; VITAMIN D;

EID: 0034756101     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Glucocorticoid-induced osteoporosis: Pathogenesis and management
2. Recommendations for the prevention and the treatment of glucocorticoid-induced osteoporosis
3. Effects of prednisone and deflazacort on vertebral bone mass
4. Effect on single oral doses of prednisone and deflazacort on human lymphocyte distribution and function. Analysis with monoclonal antibodies
5. Potency ratio - A brief synopsis
6. Establishment of the relative antiinflammatory potency of deflazacort and prednisone in polymyalgia rheumatica
7. Alendronate and estrogen effects in postmenopausal women with low bone mineral density
8. A competitive protein binding assay for 25-dihydrocholecalciferol and 25-hydroxyergocalciferol in serum
9. Clinical evidence of a new glucocorticoid, deflazacort, and prednisone in rheumatoid arthritis and SLE patients
10. Deflazacort: A review of its pharmacological properties and therapeutic efficacy
11. Comparison of subacute effects of oxazacort and prednisone on mineral metabolism in man
12. A double blind study of deflazacort and prednisone in patients with chronic inflammatory disorders
13. Glucocorticoid-induced osteoporosis in the lumbar spine, forearm, and mandible of nephrotic patients: A double-blind study on the high-dose, long-term effects of prednisone versus deflazacort
14. Effects of deflazacort versus prednisone on bone mass, body composition and lipid profile. A randomized double blind study in kidney transplant patients
15. A histomorphometric longterm longitudinal study of trabecular bone loss in glucocorticoidtreated patients. Prednisone versus deflazacort
16. Changes in bone mass during low dose corticosteroid treatment in patients with polymyalgia rheumatica: A double blind, prospective comparison between prednisolone and deflazacort
17. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis
18. Deflazacort and bone mass
19. The role of vitamin D in corticoid-induced osteoporosis
20. Calcium and vitamin D supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis
21. Combined therapy with estrogen and etidronate has an addictive effect on bone mineral density in the hip and vertebrae: Four year randomized study
22. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids
23. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis
24. Prevention of corticosteroid-induced osteoporosis: Results of a patient survey
25. Vitamin D toxicity complicating the treatment of senile, postmenopausal, and glucocorticoid-induced osteoporosis: Four cases and a critical commentary on the use of vitamin D in these disorders
26. Management of glucocorticoid-induced osteoporosis - First, do no harm
27. Prevention of glucocorticoidinduced osteoporosis: Effect on oral 25-hydroxyvitamin D and calcium
28. Vitamin D and calcium in the prevention of corticoisteroid-induced osteoporosis: A 3 year follow-up